Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor + bortezomib + dexamethasone versus bortezomib + dexamethasone in relapsed or refractory multiple myeloma
MOH_2017-06-19_000532Phase 3Completed
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of selinexor in multiple myeloma (MM) (2 arms), sponsored by Karyopharm Therapeutics Inc. Started Mar 2017; status: completed.
02
Drugs
selinexor
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on MOH_2017-06-19_000532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-06-19_000532.